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Metabolic syndrome (MS) is a complicated disorder
comprising clinical features including obesity, hyper-
glycemia, hypertension, dyslipidemia, and insulin re-
sistance (IR). Atherosclerosis and type 2 diabetes
mellitus (DM), as major consequences of MS, are criti-
cal, global health issues [1]. Current evidence suggests
that the atherosclerotic process is regulated by interven-
ing inflammatory mechanisms. IR, a key feature in the
pathogenesis of MS, has been increasingly recognized
as playing a key role in the inflammatory processes.
Hepatitis C virus (HCV) infection is another impor-
tant global health issue. Approximately 170 million
people suffer from HCV infection and it is one of the
most important worldwide causes of cirrhosis and
hepatocellular carcinoma. A number of metabolic
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Metabolic syndrome (MS) is a complicated disorder associated with a high risk of future devel-
opment of micro- and macrovascular complications. The extrahepatic manifestations of hepatitis
C virus (HCV) infection can include multiple metabolic abnormalities. However, the extent, severity,
and characteristics of MS in HCV-infected patients have rarely been investigated in community-
based settings. This study aimed to determine the difference in prevalence and distribution of the
components of MS between HCV-infected patients and healthy controls. Multipurpose mass
screening of adults was conducted in an HCV-endemic area of Southern Taiwan. Clinical profiles
in terms of anthropometric data and MS components, as well as viral hepatitis markers, were
assessed. Two hundred and thirty-seven adults (94 males; mean age, 55.5 ± 10.8 years) were
recruited. The prevalence of anti-HCV seropositivity was 39.2% (93/237). The prevalence of MS was
higher in the HCV-infected individuals (24.7%, 23/93) than in the control, uninfected subjects
(13.2%, 19/144, p = 0.02). In terms of MS components, HCV-infected subjects had a higher preva-
lence of high waist circumference (51.6% vs. 25.7%, p < 0.001) and hypertension (58.1% vs. 36.8%,
p = 0.001) than controls. Multivariate logistic regression analysis demonstrated that anti-HCV
positivity was significantly associated with MS (odds ratio, 6.4; 95% confidence interval, 1.82–22.84;
p = 0.004). HCV infection was associated with a higher prevalence of MS. Determination of MS in
patients with HCV infection could therefore be indicated.
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disturbances have been shown to be directly and indi-
rectly associated with HCV infection. An association
between HCV infection and lipid metabolism has been
consistently reported [2–4]. Lower total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C) and
triglyceride (TG) levels are commonly seen in patients
with chronic HCV infection (CHC), compared with
normal subjects. Hepatic steatosis is a common histo-
logic feature of CHC and is observed in 30–70% of
patients [5,6]. Many factors are known to increase the
risk of hepatic steatosis, including DM, hyperlip-
idemia, and obesity [7]. In addition to its hepatotropic
characteristic, HCV infection is associated with the
pathogenesis of IR, though the underlying biological
mechanisms are diverse and multifactorial. Both
experimental and clinical studies have shown that IR
often emerges at a young age or during the early
stages of histologic liver changes [8,9]. Furthermore,
emerging lines of clinical evidence have revealed that
several metabolic disturbances, such as obesity, IR, and
hepatic steatosis, are significant risk factors for de-
creased treatment response to combined pegylated
interferon and ribavirin antiviral therapy in CHC
patients [6,10–12]. IR and its related inflammatory
processes thus appear to contribute not only to MS,
but also to the metabolic disturbances associated
with HCV infection. However, the characteristic fea-
tures of MS in CHC patients have not been fully elu-
cidated. Previous studies addressing the association
between HCV infection and MS were mainly hospital-
based and the extent, severity, and characteristics of
MS in HCV-infected patients, compared with non-
HCV subjects, have rarely been investigated in 
community-based settings.
This study aimed to determine the difference in
the prevalence and distribution of MS between HCV-
infected patients and healthy controls in an HCV-
endemic area.
PATIENTS AND METHODS
Patient selection
Tzukuan Township is located in southern Taiwan
and is a hyper-endemic area for HCV infection, in both
adults and adolescents. Our previous studies demon-
strated that the prevalence of anti-HCV seropositiv-
ity (anti-HCV+) in Tzukuan Township reached 41.6%
among adult residents, with an annual incidence of
4.5%. Moreover, about 90% of hepatocellular carcinoma
cases in this township were HCV-related [9,13–15].
Based on occupational and geographic data, seven
villages along the southwest coast were classified as
maritime, while the other eight were non-maritime.
Our previous study showed that the prevalence of
HCV infection was markedly higher in the maritime
area, compared with the non-maritime area. A multi-
purpose health surveillance study was conducted in
three hyper-endemic maritime villages in March
2007. A total of 396 adults participated in this study on
a voluntary basis. After excluding those who refused
examination (55, 13.9%), those who failed to com-
plete the study (50, 12.6%), those who were very el-
derly (46, 11.6%), and those who had received prior
antiviral therapy (8, 2.0%), a total of 237 adults con-
stituted the study population.
Study design
All subjects underwent a 12-hour overnight fast before
blood tests. Blood was analyzed for anti-HCV anti-
body, fasting plasma glucose (FPG), TC, HDL-C,
LDL-C, TG, and alanine aminotransferase (ALT) levels.
Anthropometric data including body weight, height,
and blood pressure were measured using standard-
ized techniques. Research staff administered a ques-
tionnaire covering medical history, drug history,
possible parenteral risk history, and family history. Ver-
bal or written informed consent for interviews, anthro-
pometric measurements, blood sampling, and medical
record reviews were obtained from patients prior to
enrolment. The study was approved by the ethics com-
mittee of Kaohsiung Medical University Hospital.
Definition of MS
MS was defined based on the updated National
Cholesterol Education Program Adult Treatment Panel
III criteria for Asian-Americans, modified by the cri-
teria of obesity proposed for Asians by the Steering
Committee of the Regional Office for the Western
Pacific Region of WHO [1,16]. This requires the pres-
ence of at least three of the following components: 
(1) waist circumference > 90 cm in men or > 80 cm in
women; (2) TG > 150 mg/dL; (3) HDL-C < 40 mg/dL
in men or < 50 mg/dL in women; (4) blood pressure
> 130/85 mmHg or current use of antihypertensive
medications; (5) FPG > 100 mg/dL or use of oral anti-
diabetic agents or insulin.
Laboratory analyses
Hepatitis B surface antigen and anti-HCV antibody
were detected using a third-generation, commercially
available enzyme-linked immunosorbent assay kit
(AxSYM 3.0; Abbott Laboratories, Chicago, IL, USA).
Detection of serum HCV RNA was performed using
a standardized automated qualitative reverse tran-
scription-polymerase chain reaction assay (COBAS
AMPLICOR Hepatitis C Virus Test, version 2.0; Roche,
Branchburg, NJ, USA). The detection limit was 50 IU/
mL. HCV genotypes 1a, 1b, 2a, 2b, and 3a were deter-
mined by the Okamoto method [17]. FPG, TC, TG, and
ALT levels were measured using a multichannel auto-
analyzer (Hitachi Inc., Tokyo, Japan). Fasting serum
insulin levels were measured by radioimmunoassay
(Diagnostic Products, Los Angeles, CA, USA).
IR and β-cell function were calculated based on FPG
and insulin levels, according to the homeostasis model
assessment (HOMA) method [18]. The formulae for
the HOMA model are as follows: β-cell function
(HOMA-%B)= fasting insulin level (μU/mL)×360/
[FPG (mg/dL) − 63]; IR (HOMA-IR) = FPG (mg/dL) ×
fasting insulin level (μU/mL)/405.
Statistical analysis
Frequencies were compared between groups using
the χ2 test with Yates’s correction for categorical 
variables and Student’s t test for continuous vari-
ables. Results were expressed as mean±standard devi-
ation. A p value < 0.05 was considered statistically
significant. Univariate and multivariate logistic regres-
sion analyses were conducted to explore the factors
that were independently associated with MS. The
strength of association was presented as odds ratio
(OR) with 95% confidence intervals (CI) and p values.
Quality control procedures, database processing and
analyses were performed using the SPSS 12.0 statisti-
cal package (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 237 sex- and age-matched subjects (93 anti-
HCV+ and 144 anti-HCV−) were recruited and their
basic demographic characteristics are shown in Table 1.
Fifty-six anti-HCV+ subjects (60.2%) were positive
for HCV RNA (36 of genotype 1, 17 of genotype 2,
and 3 of unclassified genotype infection). Forty-two
subjects (17.7%) fulfilled the criteria for MS. The
prevalence of anti-HCV+ was 39.2% (93/237). The
anti-HCV+ subjects had a higher prevalence of hy-
pertension, and higher waist circumference, ALT lev-
els, insulin levels, HOMA-IR, and HOMA-%B than
the anti-HCV− subjects. The TC and LDL-C levels
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Table 1. Basic characteristics of anti-HCV-seropositive and -negative subjects*
Variables
Anti-HCV
pAll subjects (n = 237)
Positive (n = 93) Negative (n = 144)
Age (yr) 55.5 ± 10.8 57.1 ± 9.0 54.5 ± 11.7 NS
Male 94 (39.7) 33 (35.5) 61 (42.4) NS
Hypertension 107 (45.1) 54 (58.1) 53 (36.8) 0.001
BMI (kg/m2) 24.9 ± 3.7 25.4 ± 3.5 24.6 ± 3.9 NS
Waist circumference (cm) 80.2 ± 11.0 82.5 ± 10.5 78.7 ± 11.1 0.01
ALT (U/L) 26.6 ± 26.6 36.3 ± 36.2 20.3 ± 15.0 <0.001
FPG (mg/dL) 101.6 ± 40.8 105.3 ± 48.3 95.9 ± 24.3 NS
TC (mg/dL) 183.8 ± 32.9 176.1 ± 33.3 188.8 ± 31.7 <0.01
HDL-cholesterol 58.1 ± 15.0 56.1 ± 13.3 59.4 ± 15.9 NS
LDL-cholesterol 120.6 ± 34.3 113.1 ± 35.6 125.4 ± 32.7 0.01
Triglycerides (mg/dL) 110.0 ± 64.6 102.9 ± 54.8 114.6 ± 69.9 NS
Uric acid (mg/dL) 6.0 ± 1.5 6.2 ± 1.6 5.8 ± 1.5 NS
Insulin (μU/mL) 10.3 ± 7.6 12.5 ± 9.7 8.8 ± 5.3 0.001
HOMA-IR 1.8 ± 0.1 2.2 ± 0.3 1.6 ± 0.2 0.02
HOMA-%B 103.2 ± 7.3 128.2 ± 13.4 87.1 ± 8.1 0.01
Metabolic syndrome 42 (17.7) 23 (24.7) 19 (13.2) 0.02
*Data presented as mean ± standard deviation or n (%). HCV = hepatitis C virus; BMI = body mass index; ALT = alanine aminotrans-
ferase; FPG = fasting plasma glucose; TC = total cholesterol; HDL = high-density lipoprotein; LDL = low-density lipoprotein; HOMA =
homeostasis model assessment; IR = insulin resistance; %B = β-cell function.
were significantly lower in the anti-HCV+ subjects
compared with the anti-HCV− subjects. Overall, the
anti-HCV+ subjects had a higher prevalence of MS
(24.7%, 23/93) than the anti-HCV− subjects (13.2%,
19/144, p = 0.02).
The prevalences of high waist circumference (51.6%
vs. 25.7%, p<0.001) and hypertension (58.1% vs. 36.8%,
p = 0.001) were significantly higher in anti-HCV+ sub-
jects compared with anti-HCV− subjects (Figure).
There were no significant differences between anti-
HCV+ and anti-HCV− subjects in terms of high TG
levels (21.5% vs. 19.4%, p = 0.7), low HDL-C levels
(19.4% vs. 18.1%, p = 0.8), and DM (22.6% vs. 29.9%,
p = 0.2).
Regarding the age-specific distribution of MS, the
prevalence of MS among anti-HCV+ subjects aged
40–60 years was higher (25.5%, 14/55) than that of
controls (10.6%, 10/94; p = 0.02). For those aged ≥ 60
years, the prevalence was not higher in anti-HCV+
subjects (25.7%, 9/35) compared with controls (18.9%,
7/37; p = 0.5).
Multivariate logistic regression analyses were con-
ducted to clarify the independent factors associated
with MS. Variables included age, sex, body mass index
(BMI), ALT, creatinine, uric acid, FPG, HDL-C levels,
and the presence of hypertension and IR. Anti-HCV+
was significantly associated with MS (OR, 6.4; 95%
CI, 1.82–22.84; p = 0.004) as well as with hypertension,
BMI, and HDL-C (Table 2).
DISCUSSION
The unique HCV hyper-endemic geographic back-
ground of the current case-control study allowed us
to examine the association between HCV infection
and MS. Our data demonstrated that HCV infection
was associated with an increased prevalence of MS,
compared with that in non-HCV-infected subjects.
High waist circumference and hypertension were the
common features of MS in subjects with HCV infec-
tion. We also demonstrated that anti-HCV+ subjects
had a higher prevalence of IR than anti-HCV− sub-
jects. IR plays a key role in the emergence of MS, and
our data may thus further suggest that HCV infec-
tion contributes to the risk of developing MS.
Subjects with MS generally have higher rates of IR
and are therefore also at increased risk of developing
type 2 DM, as well as future micro- and macrovascu-
lar complications [19,20]. Previous reports have indi-
cated that metabolic abnormalities, including liver
steatosis, obesity and DM, can worsen the course of
CHC [21,22]. In addition, CHC has a direct steato-
genic effect on liver cells and may be involved in the
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Table 2. Multivariate logistic regression analyses of variables associated with metabolic syndrome
Variables* OR 95% CI p
Hypertension Positive = 1, Negative = 0 31.8 6.49–155.84 < 0.001
Anti-HCV+ Positive = 1, Negative = 0 6.4 1.82–22.84 0.004
BMI (kg/m2) Per 1 kg/m2 increase 1.3 1.09–1.51 0.002
HDL-C (mg/dL) Per 1 mg/dL increase 0.9 0.88–0.98 0.009
*Variables included age, sex, body mass index (BMI), aminotransferase, creatinine, uric acid, fasting plasma glucose, high-density
lipoprotein cholesterol (HDL-C) levels, and the presence of hypertension and insulin resistance. For the continuous variables, OR
represents one unit increase in the value of the variable tested. OR = odds ratio; CI = confidence interval; HCV = hepatitis C virus.
Anti-HCV+
Anti-HCV−
51.6
58.160
p < 0.001
36.840
50
25.7
22.6
29.9
30%
21.5 19.4 19.4 18.1
10
20
0
MS1 MS2 MS3 MS4 MS5
p = 0.001
Figure. Distribution of metabolic syndrome components in rela-
tion to anti-hepatitis C virus (HCV ) seropositivity. MS1 = waist
circumferences >90cm in men or >80cm in women; MS2 = triglyc-
eride level >150 mg/dL; MS3 = high-density lipoprotein cholesterol
< 40 mg/dL in men or < 50 mg/dL in women; MS4 = blood pres-
sure > 130/85 mmHg or current use of antihypertensive medica-
tions; MS5 = type 2 diabetes or use of oral antidiabetic agents or
insulin.
development of type 2 DM [22–24]. However, the cor-
relation between MS and HCV infection has rarely
been investigated in clinical settings. We demonstrated
that subjects with HCV infection were at increased
risk of developing MS. This suggests that patients
with HCV infection should be evaluated for the pres-
ence of MS, while lifestyle changes directed at increas-
ing physical activity, optimal weight maintenance,
and diet composition should be emphasized.
The precise biological mechanisms whereby HCV
infection leads to MS are not fully understood. HCV
may induce a Th1 lymphocyte immune-mediated
response, leading to activation of the tumor necrosis
factor (TNF)-α system and elevation of interleukin-6
levels. Meanwhile, HCV directly causes liver steatosis.
A combination of these events may result in the devel-
opment of liver fibrosis. TNF-α system activation,
liver steatosis, and fibrosis in turn contribute to the
development of IR, which plays a pivotal role in the
development of MS [25]. HCV-induced inflammatory
changes may subsequently lead to increased oxida-
tive stress and peroxidation, which evoke higher sys-
temic inflammatory responses. Our results therefore
imply that, in addition to the direct hepatotropic
effects of HCV infection, MS should be considered as a
possible extrahepatic manifestation of HCV [24,26–28].
The current study demonstrated that anti-HCV+
subjects had significantly lower TC and LDL-C levels
and lower HDL-C and TG levels than anti-HCV−
subjects. These data are in agreement with those 
from previous experimental and clinical studies that
addressed the association between HCV infection and
lipid metabolism [3,29]. HCV infection was shown to
be associated with significantly lower cholesterol (TC,
HDL-C and LDL-C) and TG levels compared with
normal subjects [2,3] and a recent study demonstrated
that TC, LDL-C and TG levels increased after suc-
cessful eradication of HCV genotype-1 infection with
antiviral therapy [30]. Although our study failed to
show significant differences in TG and HDL-C levels
between anti-HCV+ and anti-HCV− subjects, further
long-term studies aimed at assessing the changing
features of MS after antiviral therapy are warranted.
In addition, the relative risk of atherosclerotic cardio-
vascular disease in patients with MS and HCV infec-
tion, compared with non-HCV subjects, deserves
further investigation.
The increasing burden of obesity is the driving
force behind the rising prevalence of MS. Body fat
distribution, particularly excess abdominal fat, plays
an important role in the etiology of MS [1]. Regardless
of the relative contributions of visceral fat and abdom-
inal subcutaneous fat to IR, abdominal (or upper-
body) obesity correlates more strongly with IR and 
MS than does lower-body obesity [31]. Our previous
study also demonstrated that the discrepancy in
prevalence of MS between CHC patients and controls
was inversely related to age, suggesting that HCV
infection may contribute to the subtle development of
glucose abnormalities at a younger age [9]. Intrigu-
ingly, the current study showed that anti-HCV+
subjects had a significantly higher mean waist cir-
cumference than anti-HCV− subjects. This may some-
how reflect the common observation that IR is a
general feature of HCV infection. However, the cross-
sectional nature of the current study and incomplete
coverage of all genotypes did not allow us to reach a
definite conclusion on this issue. A large collabora-
tive study comparing patients with different HCV
genotypesis needed to further clarify any relation-
ship between genotype and predisposition to or 
protection from MS. A well-designed longitudinal
follow-up study is also warranted to further clarify if
HCV infection predisposes to the development of
upper-body obesity.
In conclusion, we demonstrated that HCV infection
was associated with an increased prevalence of MS.
High waist circumference and presence of hyperten-
sion were the common features of MS in patients
with HCV infection. Our data indicate a possible link
between HCV infection and MS and suggest that
assessment of MS in patients with HCV infection
may therefore be warranted.
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C 型肝炎感染與代謝症候群 — 
一個台灣 C 型肝炎高盛行地區之社區研究
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代謝症候群是一個複雜的疾病且具有發生小血管及大血管併發症之高風險。C 型肝炎
感染在肝外的表現常見許多代謝上的異常，然而卻極少有社區流行病學的研究來探討 
C 型肝炎病人代謝症候群的發生率、嚴重性及特徵。本研究的目的在於探討 C 型肝炎
病人及健康對照組之間代謝症候群構成因素的發生率及分布。本研究在一南部 C 型肝
炎高盛行地區共收集 237 位成年人 (94 位男性，平均年齡 55.5 ± 10.8 歲 )，其中 C 
型肝炎抗體陽性發生率為 39.2% (93/237)。93 位 C 型肝炎感染病人 (24.7%，
23/93) 相較於健康對照組 (13.2%，19/144，p = 0.02) 有較高的代謝症候群發生
率。在代謝症候群構成因素方面，高腰圍 (51.6% vs. 25.7%，p < 0.001) 及高血壓 
(58.1% vs. 36.8%，p = 0.001) C 型肝炎病患相較健康對照組有較高的發生率。本研
究顯示 C 型肝炎病患有較高的代謝症候群發生率，因此可建議其接受代謝症候群之篩
檢。
關鍵詞：C 型肝炎，胰島素耐受性，代謝症候群
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